tetano
Editor, Senior Moderator
Front Immunol
. 2023 Jul 21;14:1203803.
doi: 10.3389/fimmu.2023.1203803. eCollection 2023. Evaluation of humoral immune response in relation to COVID-19 severity over 1 year post-infection: critical cases higher humoral immune response than mild cases
Mi-Seon Bang[SUP] 1 [/SUP], Choon-Mee Kim[SUP] 2 [/SUP], Nam-Hyuk Cho[SUP] 3 [/SUP], Jun-Won Seo[SUP] 1 [/SUP], Da Young Kim[SUP] 1 [/SUP], Na Ra Yun[SUP] 1 [/SUP], Dong-Min Kim[SUP] 1 [/SUP]
Affiliations
Introduction: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2. We investigated the antibody response against SARS-CoV-2 until 1 year after symptom onset.
Methods: We collected 314 serum samples from 97 patients with COVID-19. Antibody responses were tested using an indirect immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and plaque reduction neutralization test (PRNT) to detect specific neutralizing antibodies.
Results: The positivity rates for neutralizing antibodies at a 1:10 titer cutoff were 58.1% at 1 week, 97.8% at 4 weeks, and 78% at 1 year after symptom onset (53.8% in asymptomatic patients and 89.3% in symptomatic patients). The IFA and anti-S1 ELISA IgG results significantly correlated with neutralizing antibody titers. Critical/fatal cases showed significantly higher antibody titers than the asymptomatic or mild-to-moderate illness groups. Nonetheless, the median number of days to the seroconversion of neutralizing antibodies was 10 and 15 in asymptomatic and symptomatic patients, respectively. The asymptomatic group had a significantly higher neutralizing potency index than the mild-to-severe illness groups.
Conclusions: Neutralizing antibodies corresponded to earlier seroconversion but had a shorter presence in the asymptomatic group than in the symptomatic group and were still present 1 year after symptom onset in critical/fatal cases.
Keywords: 1-year follow-up; COVID-19; antibody response; neutralization potency; neutralizing antibody; severe acute respiratory syndrome coronavirus 2.
. 2023 Jul 21;14:1203803.
doi: 10.3389/fimmu.2023.1203803. eCollection 2023. Evaluation of humoral immune response in relation to COVID-19 severity over 1 year post-infection: critical cases higher humoral immune response than mild cases
Mi-Seon Bang[SUP] 1 [/SUP], Choon-Mee Kim[SUP] 2 [/SUP], Nam-Hyuk Cho[SUP] 3 [/SUP], Jun-Won Seo[SUP] 1 [/SUP], Da Young Kim[SUP] 1 [/SUP], Na Ra Yun[SUP] 1 [/SUP], Dong-Min Kim[SUP] 1 [/SUP]
Affiliations
- PMID: 37545518
- PMCID: PMC10401267
- DOI: 10.3389/fimmu.2023.1203803
Introduction: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2. We investigated the antibody response against SARS-CoV-2 until 1 year after symptom onset.
Methods: We collected 314 serum samples from 97 patients with COVID-19. Antibody responses were tested using an indirect immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and plaque reduction neutralization test (PRNT) to detect specific neutralizing antibodies.
Results: The positivity rates for neutralizing antibodies at a 1:10 titer cutoff were 58.1% at 1 week, 97.8% at 4 weeks, and 78% at 1 year after symptom onset (53.8% in asymptomatic patients and 89.3% in symptomatic patients). The IFA and anti-S1 ELISA IgG results significantly correlated with neutralizing antibody titers. Critical/fatal cases showed significantly higher antibody titers than the asymptomatic or mild-to-moderate illness groups. Nonetheless, the median number of days to the seroconversion of neutralizing antibodies was 10 and 15 in asymptomatic and symptomatic patients, respectively. The asymptomatic group had a significantly higher neutralizing potency index than the mild-to-severe illness groups.
Conclusions: Neutralizing antibodies corresponded to earlier seroconversion but had a shorter presence in the asymptomatic group than in the symptomatic group and were still present 1 year after symptom onset in critical/fatal cases.
Keywords: 1-year follow-up; COVID-19; antibody response; neutralization potency; neutralizing antibody; severe acute respiratory syndrome coronavirus 2.